Non-metastatic Prostate Cancer Clinical Trial
Official title:
A Feasibility and Safety Study of Focal Interstitial Radiotherapy Using Diffusing Alpha Emitters Radiation Therapy (DaRT) Seeds in Men With Non-metastatic Locally Recurrent Prostate Cancer.
This is a multi-center clinical study enrolling up to 10 participants. The purpose of this study is to assess the feasibility and safety of intratumoral DaRT seeds implantation for the treatment of locally recurrent prostate cancer. Secondary objectives are to 1. To evaluate feasibility of interstitial radiotherapy using DaRT seeds. Feasibility will be determined according to the rate of successful placement of DaRT seeds via imaging [Timeframe: immediately following the insertion procedure 2. To assess the impact of DaRT seeds on patient reported quality of life.
This study is a prospective multicenter, single arm, open label , interventional clinical study to assess the feasibility and safety of intratumoral Alpha DaRT seeds for the treatment of men with non metastatic locally recurrent prostate cancer. Diffusing Alpha emitters Radiation Therapy (DaRT). Treatment will be delivered through radioactive sources [Ra-224 containing Stainless steel 316LVM tubes- (Alpha DaRT seeds)] inserted into the tumors. The purpose of this study is to assess the feasibility and safety of intratumoral DaRT seeds implantation for the treatment of locally recurrent prostate cancer. The secondary objectives is 1. To evaluate feasibility of interstitial radiotherapy using DaRT seeds. Feasibility will be determined according to the rate of successful placement of DaRT seeds via imaging [Timeframe: immediately following the insertion procedure 2. To assess the impact of DaRT seeds on patient reported quality of life. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04400656 -
PROState Pathway Embedded Comparative Trial
|
||
Completed |
NCT00673205 -
(Bicalutamide) Casodex vs Placebo in Non-metastatic Early Prostate Cancer
|
Phase 3 | |
Completed |
NCT00672282 -
Casodex vs Placebo in Non-Metastatic Early Prostate Cancer
|
Phase 3 | |
Recruiting |
NCT01317043 -
A Trial of Samarium 153 Followed by Salvage Prostatic Fossa 3D-CRT or IMRT Irradiation in High-Risk, Clinically Non-Metastatic Prostate Cancer After Radical Prostatectomy
|
Phase 2 | |
Completed |
NCT06204302 -
An Observational Study to Learn More About the Use of Androgen Receptor Inhibitors and How They Affect Men With Nonmetastatic Prostate Cancer in Routine Medical Care in the United States
|
||
Completed |
NCT00239291 -
Safety Study to Explore Combination of Gefitinib (ZD1839, Iressa) and Radiotherapy in Non-Metastatic Prostate Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT04049747 -
Comparative Health Research Outcomes of NOvel Surgery in Prostate Cancer
|
N/A | |
Active, not recruiting |
NCT05617885 -
Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT00657904 -
Bicalutamide (Casodex™) Versus Placebo in Patients With Early Prostate Cancer
|
Phase 3 |